Skip to main content
. 2019 Nov 4;180(1):70–79. doi: 10.1001/jamainternmed.2019.4802

Figure 3. Medication Dose Changes From Baseline for Each Diabetes Medication Class by Arm for Participants Who Attended Week 48.

Figure 3.

DPP-4 indicates dipeptidyl peptidase 4 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist; GMV, group medical visit; SGLT-2, sodium-glucose co-transporter-2 inhibitors; and WM, weight management.